Literature DB >> 8478659

Role of computed tomography in the staging of primary melanoma.

A C Buzaid1, A B Sandler, S Mani, A M Curtis, W J Poo, J L Bolognia, S Ariyan.   

Abstract

PURPOSE: To evaluate the role of body computed tomography (CT) for the staging of patients with early melanoma. PATIENTS AND METHODS: A total of 151 new patients with American Joint Committee (AJC) clinical stage I, II, and III melanoma who received a CT scan of at least the chest and abdomen are the subject of this study. CT scans considered suspicious for metastases were reviewed again by one of the investigators (A.McB.C.).
RESULTS: Of 151 patients, 63 had AJC clinical stage I, 61 stage II, and 23 stage III disease. In addition, one patient each had primary melanoma of the anal canal, esophagus, or vulva. Twenty-nine (19%) of 151 patients had a CT scan that was considered suspicious for metastases. The most common radiologic findings were single hepatic, and single or multiple pulmonary nodules. Of these 29 patients with suspicious scans, 24 subsequently proved to have benign processes by biopsy or follow-up studies, three had second primary tumors (well-differentiated lymphocytic lymphoma, Hodgkin's disease, and renal cell carcinoma), and only two were found to have metastatic melanoma. Of these two patients, one had regional nodal disease (unsuspected on physical examination) and one had distant nodal metastases.
CONCLUSION: Body CT is not a useful imaging study in the detection of occult metastases in patients with primary melanoma. Although body CT commonly shows suspicious radiologic abnormalities in patients with early melanoma, these abnormalities most likely represent benign processes or a second primary tumor, rather than metastatic melanoma. The value of body CT in patients who present with nodal metastases needs further study.

Entities:  

Mesh:

Year:  1993        PMID: 8478659     DOI: 10.1200/JCO.1993.11.4.638

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  11 in total

1.  Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines.

Authors:  Emanuela Romano; Michael Scordo; Stephen W Dusza; Daniel G Coit; Paul B Chapman
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

Review 2.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

3.  Malignant melanoma in children: imaging spectrum.

Authors:  S C Kaste; A S Pappo; J J Jenkins; C B Pratt
Journal:  Pediatr Radiol       Date:  1996-11

4.  Primary oesophageal malignant melanoma.

Authors:  David A Westwood; Jeffrey B Macemon; Grant N Coulter; Teresa A Chalmers-Watson; Ross H Roberts
Journal:  J Gastrointest Surg       Date:  2010-12-02       Impact factor: 3.452

5.  PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging.

Authors:  Yulia Bronstein; Chaan S Ng; Eric Rohren; Merrick I Ross; Jeffrey E Lee; Janice Cormier; Valen E Johnson; Wen-Jen Hwu
Journal:  AJR Am J Roentgenol       Date:  2012-04       Impact factor: 3.959

6.  The role of routine imaging in pediatric cutaneous melanoma.

Authors:  Hadeel Halalsheh; Sue C Kaste; Fariba Navid; Armita Bahrami; Barry L Shulkin; Bhaskar Rao; Michelle Kunkel; Nathan Artz; Alberto Pappo
Journal:  Pediatr Blood Cancer       Date:  2018-08-19       Impact factor: 3.167

7.  Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis.

Authors:  Yan Xing; Yulia Bronstein; Merrick I Ross; Robert L Askew; Jeffrey E Lee; Jeffrey E Gershenwald; Richard Royal; Janice N Cormier
Journal:  J Natl Cancer Inst       Date:  2010-11-16       Impact factor: 13.506

8.  Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival.

Authors:  Jan Zakrzewski; Laurel N Geraghty; Amy E Rose; Paul J Christos; Madhu Mazumdar; David Polsky; Richard Shapiro; Russell Berman; Farbod Darvishian; Eva Hernando; Anna Pavlick; Iman Osman
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

9.  Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients.

Authors:  Neha Singh; Nora A Alexander; Kristina Lachance; Christopher W Lewis; Aubriana McEvoy; Gensuke Akaike; David Byrd; Sanaz Behnia; Shailender Bhatia; Kelly G Paulson; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2020-07-21       Impact factor: 11.527

Review 10.  Staging of cutaneous melanoma.

Authors:  P Mohr; A M M Eggermont; A Hauschild; A Buzaid
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.